Your browser doesn't support javascript.
loading
Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects.
Shen, Hong; Chen, Weiqi; Drexler, Dieter M; Mandlekar, Sandhya; Holenarsipur, Vinay K; Shields, Eric E; Langish, Robert; Sidik, Kurex; Gan, Jinping; Humphreys, W Griffith; Marathe, Punit; Lai, Yurong.
Afiliación
  • Shen H; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers
  • Chen W; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers
  • Drexler DM; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers
  • Mandlekar S; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers
  • Holenarsipur VK; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers
  • Shields EE; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers
  • Langish R; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers
  • Sidik K; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers
  • Gan J; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers
  • Humphreys WG; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers
  • Marathe P; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers
  • Lai Y; Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers
Drug Metab Dispos ; 45(8): 908-919, 2017 08.
Article en En | MEDLINE | ID: mdl-28576766
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ácidos Palmíticos / Ácidos y Sales Biliares / Biomarcadores / Sulfato de Deshidroepiandrosterona / Coproporfirinas / Transportadores de Anión Orgánico Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Humans / Male / Middle aged Idioma: En Revista: Drug Metab Dispos Asunto de la revista: FARMACOLOGIA Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ácidos Palmíticos / Ácidos y Sales Biliares / Biomarcadores / Sulfato de Deshidroepiandrosterona / Coproporfirinas / Transportadores de Anión Orgánico Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Humans / Male / Middle aged Idioma: En Revista: Drug Metab Dispos Asunto de la revista: FARMACOLOGIA Año: 2017 Tipo del documento: Article